Thank you very much for the opportunity. I would like to know how many MRs do we have on field for semaglutide in India? And what would be the strategy? How many do we actually require?
Okay. And my second question for the Adcock, how much CAGR can we consider for the Adcock's revenue and the PAT?
So my question is on the product. So 4 assets that we mentioned on the multi-specific platform, are they all trispecific antibodies or also various other antibody formats like bispecific, scFv, Fab, etc? And the second question is about the time line that you mentioned 5 years. Is this a time line for recognition of the revenue, out -licensing revenue from these 4 assets? Or is this a time line for these preclinical assets to enter the clinical Phase I?